COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

September 16-21, 2021; Virtual
Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 319 KB
Released: September 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in androgen deprivation therapy for prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: October 6, 2021 Expired: October 5, 2022

Health-related quality of life, pain, safety outcomes from VISION trial of 177Lu-PSMA-617 in men with mCRPC presented at the 2021 ESMO Congress, reported by Clinical Care Options (CCO)

Released: September 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue